Categories AlphaGraphs, Earnings, Health Care

MEDS Earnings: Trxade Health Q2 revenues surge 73% amid continued user growth

Trxade Health Inc (NASDAQ: MEDS), a leading health service IT company, reported a sharp increase in its second-quarter 2022 revenues. The top line also exceeded experts’ consensus estimates.

Trxade Q2 2022 earnings infographic

Second-quarter revenues jumped 73% from last year to $3.28 million, which also came in above analysts’ estimates. Consequently, the company’s net loss narrowed to $1.08 million or $0.13 per share in the June quarter from $2.58 million or $0.32 per share in the comparable period of fiscal 2021

Continuing the expansion of its drug procurement marketplace nationwide, the company added 319 new registered members in the second quarter and 685 new members during the first half of 2022. It had around 13,816 registered members at the end of the quarter.

“2022 is an exciting time for TRxADE, as we continue to position ourselves to create sustainable value for our stockholders. I am pleased with the growth we have experienced in our TRxADE and TRxADE Prime platforms. We continue to achieve several key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities,” said Trxade’s CEO Suren Ajjarapu.

Check this space to read management/analysts’ comments on Trxade’s Q2 2022 results

Shares of Trxade traded higher early Tuesday, extending the post-earnings uptrend. They have gained about 24% in the past thirty days.

Prior Performance

  • Trxade Q1 2022 earnings infographic
  • Trxade Q4 2021 earnings infographic
  • Trxade Health Q3 2021 earnings
  • Trxade Health Q2 2021 earnings
  • Trxade Q1 2021 earnings

Most Popular

TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel

TC BioPharm (NASDAQ: TCBP) is a clinical-stage cell therapy company focused on the development of treatments for infectious diseases, including advanced allogeneic chimeric antigen receptor (CAR) T-cell therapy products for

Cintas Corp. (CTAS) Q3 2023 earnings and revenue increase

Uniform rental company Cintas Corporation (NASDAQ: CTAS) on Wednesday announced financial results for the third quarter of 2023, reporting higher earnings and revenues. At $2.19 billion, third-quarter revenues were up

Infographic: Micron (MU) reports net loss for Q2; revenue down 53%

Micron Technology Inc. (NASDAQ: MU) slipped to a loss in the second quarter of 2023 from a profit last year, hurt by a sharp fall in revenues. The chipmaker reported

Add Comment
Viewing Highlight